Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 32Terminated 9Unknown 8Active not recruiting 5Recruiting 4Withdrawn 3Not yet recruiting 1Available 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 5

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 4Burkitt Lymphoma 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Substance Withdrawal Syndrome 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Leukemia, Biphenotypic, Acute 1Glioma 1Frailty 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 12fludarabine 11fludarabine phosphate 8Tacrolimus 8Melphalan 8Whole-Body Irradiation 7Mycophenolic Acid 7Thiotepa 6Imatinib Mesylate 6nilotinib 5Granulocyte Colony-Stimulating Factor 5Dasatinib 5Busulfan 5venetoclax 4ponatinib 4asciminib 4Mesna 4bosutinib 3Sirolimus 3Peripheral Blood Stem Cell Transplantation 3thymoglobulin 2ruxolitinib 2blinatumomab 2Patient Reported Outcome Measures 2Filgrastim 2Antilymphocyte Serum 2selinexor 1plerixafor 1Triamcinolone 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Dasatinib × Clear all
NCT00070499 2026-05-29

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
406 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04626024 2026-05-04

TOKIN

Baylor College of Medicine

Phase 2 Active not recruiting
17 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02689440 2026-03-05

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
155 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03906292 2025-03-10

CMLXI

University of Jena

Phase 2 Active not recruiting
125 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡